Pelthos Therapeutics Inc. · AMEX:PTHS
Pelthos Therapeutics — Chromocell Therapeutics — Investor Presentation (March 2024)
25 slides from Pelthos Therapeutics's investor presentation, Mar 13, 2024
Slide 1: Potential Breakthrough Drug for Non-Opioid Pain Treatment Therapies
CHROMOCELL THERAPEUTICS CORPORATION 1 CHROMOCELL THERAPEUTICS CORPORATION Potential Breakthrough Drug for Non - Opioid Pain Treatment Therapies
Slide 2: Legal Disclaimer
CHROMOCELL THERAPEUTICS CORPORATION 2 Legal Disclaimer This presentation of Chromocell Therapeutics Corporation (“we”, “us”, “our” or the “Company”) contains “forward - looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws . Words such as “a
Slide 3: Investment Highlights
CHROMOCELL THERAPEUTICS CORPORATION 3 Investment Highlights Overview • Developing patented non - opioid pain treatment therapies • Proprietary compound with good patent protection Clinical / Pre - Clinical • Phase I and toxicology completed • Pre - clinical programs are topical, and expect swifter a
Slide 4: Pain Market / Opioid Crisis
CHROMOCELL THERAPEUTICS CORPORATION 4 Pain Market / Opioid Crisis • Pain treatment is a $78B annual market in the US 1 • Using opioids for many pain indications, while efficacious, has many deleterious side effects, including: • Highly addictive • Overdose / mortality risk • Chromocell is working on
Slide 5: Pipeline
CHROMOCELL THERAPEUTICS CORPORATION 5 Pipeline Three active clinical / pre - clinical programs Asset Indication Preclinical Phase 1 Phase 2 Phase 3 Neuropathic Pain Erythromelalgia Eye Pain Acute Pain / Migraine
Slide 6: Management Team
CHROMOCELL THERAPEUTICS CORPORATION 6 Management Team Frank Knuettel | CEO & Chief Financial Officer M r . Knuettel has 30 years of management experience in growing early - stage companies . He has raised more than $ 300 million via venture, public equity and debt offerings and managed more than 15
Slide 7: Clinical & Competitive Background
CHROMOCELL THERAPEUTICS CORPORATION 7 CHROMOCELL THERAPEUTICS CORPORATION Clinical & Competitive Background
Slide 8: Sodium channels are our bodies' electrical circuits
CHROMOCELL THERAPEUTICS CORPORATION 8 Sodium channels are our bodies “electrical circuits” Non - selective (e.g. carbamazepine) block all of the NaV channel subtypes
Slide 9: Why is NaV1.7 a Good Target for Pain Treatment?
CHROMOCELL THERAPEUTICS CORPORATION 9 Why is NaV1.7 a Good Target for Pain Treatment? Insensitivity to Pain Lack of NaV 1.7 (Rare condition initially described in family from Pakistan) Severe Pain Excessive NaV 1.7 activity (e.g. Erythromelalgia) Genetic validation suggests that suppressing NaV 1.7
Slide 10: CC8464 – Development Status
CHROMOCELL THERAPEUTICS CORPORATION 10 CC8464 – Development Status Preclinical • Potent ( nM ) inhibitor of human NaV1.7; Subtype selective • Demonstrated in vivo efficacy in several rodent models of pain: Acute, chronic neuropathic, inflammatory, visceral and post - surg ical • No CNS and muscle/mo
Slide 11: Development Plan – Systemic Chronic Pain
CHROMOCELL THERAPEUTICS CORPORATION 11 CHROMOCELL THERAPEUTICS CORPORATION Development Plan – Systemic Chronic Pain
Slide 12: Phase 1 Results / Dose-Escalation Study
CHROMOCELL THERAPEUTICS CORPORATION 12 Phase 1 Results / Dose - Escalation Study Phase 1 Results • No significant dose related trends or apparent differences compared to placebo in laboratory assessments, vital signs or ECG and no dose escalation stopping criteria were met • A moderate drug - induce
Slide 13: Idiopathic Small Fiber Neuropathy Overview
CHROMOCELL THERAPEUTICS CORPORATION 13 Idiopathic Small Fiber Neuropathy Overview Symptoms and Background Most such cases present in adults ≥50 years of age and progress slowly over months to years. The symptoms are typically sensory, involving paresthesia, numbness, or pain. Electrodiagnostic studi
Slide 14: Phase 2a POC Small Fiber Neuropathy Strategy and Endpoints
CHROMOCELL THERAPEUTICS CORPORATION 14 Phase 2a POC Small Fiber Neuropathy* Strategy and Endpoints Our strategy sets two key goals for POC studies with CC8464: • Obtain results demonstrating that CC8464 is a viable therapeutic for EM patients • Demonstrate that CC8464 and its blockage of NaV1.7 is a
Slide 15: Erythromelalgia Overview
CHROMOCELL THERAPEUTICS CORPORATION 15 Erythromelalgia Overview Symptoms Erythema (heat), Pain (Usually severe burning pain but may include pins and needles or itching), Swelling, Change in perspira tio n and discoloration Types of EM Primary EM (Inherited or Sporadic SCN9A mutations + non genetic o
Slide 16: Phase 2a Pilot EM Proof of Concept Study
CHROMOCELL THERAPEUTICS CORPORATION 16 Phase 2a Pilot EM Proof of Concept Study (POC)* * The Company is planning to conduct a Phase 2 a study and the concept presented herein remains subject to change . An open label study of CC8464 in the treatment of Erythromelalgia Screening Randomization CC8464
Slide 17: Development Plan – Eye Pain
CHROMOCELL THERAPEUTICS CORPORATION 17 CHROMOCELL THERAPEUTICS CORPORATION Development Plan – Eye Pain
Slide 18: Eye Pain
CHROMOCELL THERAPEUTICS CORPORATION 18 Eye Pain Eye pain is common with both acute and chronic etiologies that include : Corneal Induced Chronic Pain from Dry Eye/NOP, Post PRK surgery, second eye cataract surgery, acute corneal abrasion, Ectropion/Entropion, Acute closed angle glaucoma, Uveitis, Ir
Slide 19: Eye Pain Treatment Program Plan
CHROMOCELL THERAPEUTICS CORPORATION 19 Eye Pain Treatment Program Plan Strategy • Develop an eye drop formula with CC - 8464 with initial 3 - month stability • Demonstrate ophthalmologic safety in rabbits • Consider animal efficacy model or progress immediately to a POC trial in humans Potential mod
Slide 20: Sublingual Programs
CHROMOCELL THERAPEUTICS CORPORATION 20 CHROMOCELL THERAPEUTICS CORPORATION Sublingual Programs
Slide 21: Sublingual Diclofenac Spray
CHROMOCELL THERAPEUTICS CORPORATION 21 Sublingual Diclofenac Spray Toxicology Diclofenac is a well characterized NSAID with well understood safety and efficacy Sublingually delivered NSAID for faster relief with no need for swallowing Exclusive Worldwide License Chromocell has an exclusive license f
Slide 22: Sublingual Rizatriptan (Maxalt) and Ondansetron (Zofran)
CHROMOCELL THERAPEUTICS CORPORATION 22 Sublingual Rizatriptan (Maxalt) and Ondansetron (Zofran) Rizatriptan (Maxalt) Treatment of acute migraine. Negates the need to swallow which is difficult during a migraine and may offer a more rapid onset. Sublingually delivered for potentially faster onset wit
Slide 23: Board of Directors & Scientific Advisory Board
CHROMOCELL THERAPEUTICS CORPORATION 23 CHROMOCELL THERAPEUTICS CORPORATION Board of Directors & Scientific Advisory Board
Slide 24: Board of Directors
CHROMOCELL THERAPEUTICS CORPORATION 24 Board of Directors Todd Davis | Chairman Mr . Davis is CEO and a member of the Board of Directors of Ligand Pharmaceuticals and has nearly 30 years of experience in biopharmaceutical and life sciences operations and investing . He has been involved in over $ 3
Slide 25: Scientific Advisory Board
CHROMOCELL THERAPEUTICS CORPORATION 25 Scientific Advisory Board (“SAB”) Stephen G. Waxman | MD, PhD, Yale School of Medicine, Chairman • Bridget Marie Flaherty Professor of Neurology, Neuroscience, and Pharmacology • Chair, Department of Neurology ( 1986 - 2009 ), Yale University School of Medicine
Chromocell Therapeutics — Investor Presentation (March 2024) on 6ix